IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment
Open Access
- 28 June 2026
- journal article
- research article
- Published by Springer Nature in Oncology and Therapy
- Vol. 14 (3) , 1-17
Abstract
Introduction Ciltacabtagene autoleucel (cilta-cel) has demonstrated deep and durable responses in patients with relapsed/refractory multiple myeloma (RRMM), supporting the goal of sustained minimal residual disease (MRD) negativity as a marker for potential functional cure, characterized by prolonged treatment-free disease control. Initially, cilta-cel was approved in the US for RRMM after ≥ 4 prior lines of therapy (LOT), and after 1–3 prior LOT in April 2024. This study describes real-world clinical outcomes, including MRD negativity, of cilta-cel after 1–3 prior LOT. Methods Electronic medical records from Loopback Analytics (April 2024–May 2025) were used, supplemented with physician notes. Adults with RRMM treated with cilta-cel after 1–3 prior LOT were included. Post-infusion outcomes (cilta-cel response, MRD negativity, disease progression, and overall survival) were assessed overall and by bridging therapy (BT) regimen. Results Overall, 120 patients were included (median age 67 years, 43.3% female). Prior to infusion, 87.5% received BT, including alkylator-based (28.6%), IMiD ± mAb-based (25.7%), PI-based (20.0%), talquetamab (14.3%), and other regimens (11.4%). Over a median follow-up of 5.8 months, among patients with a response assessment (81.7%), the overall response rate (ORR) to cilta-cel was 98.0%, including 72.4% with complete response. Among 36 MRD-evaluable patients, MRD negativity (10–5) was achieved in 35 (97.2%), with a median time to MRD negativity of 80.0 days. At last follow-up, 94.2% of patients remained progression-free, 95.8% had not initiated subsequent treatment, and 99.2% remained alive. Across BT regimens, ORR to cilta-cel was 95–100% and MRD negativity was achieved in 80–100%. Conclusions This real-world study demonstrates the effectiveness of cilta-cel in RRMM after 1–3 prior LOT. High rates of response and MRD negativity were reported overall and across BT regimens, including talquetamab. Longer follow-up with repeated MRD measurements may provide further insights into response durability and survival outcomes, helping to contextualize the potential for a functional cure. Graphical AbstractKeywords
Funding Information
- Johnson and Johnson
- Legend Biotech
This publication has 36 references indexed in Scilit:
- MRD in multiple myeloma: does CR really matter?Blood, 2022
- A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myelomaBlood Advances, 2020
- Frailty in Older Adults With Multiple Myeloma: A Study of US VeteransJCO Clinical Cancer Informatics, 2020
- Multiple myeloma current treatment algorithmsBlood Cancer Journal, 2020
- Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myelomaBMC Cancer, 2020
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapyBlood, 2017
- Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myelomaLeukemia, 2017
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe Lancet Oncology, 2016
- Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative DataMedical Care, 2005